# R1 Clinical-Safety Review — choroid_plexus_carcinoma

VERDICT: APPROVE

Reviewer: stewardmd R1 (clinical-safety, blocking gate)
Adversarial verdict file (.verdict.md): NOT PRESENT — no outstanding adversarial ISSUES to re-check.
Goldens changed: no (intended: n) — narrative-only KB content, no engine/rule/dose data touched.

## 1. Safety
No unsafe, misleading, or absolute statement found. The draft is consistently hedged:
"maximal safe surgical resection," "reasonable option," "individualized with pediatric
neuro-oncology input." No cure guarantee, no directive that could cause harm if followed.
Perioperative cautions (brisk vascular bleeding, hydrocephalus/CSF diversion) are accurate
and safety-positive. No overstep of decision-support scope.

## 2. Grounding (DeVita/NCCN standard of care)
Treatment claims are consistent with standard of care for CPC:
- Maximal safe resection as cornerstone; GTR associated with better outcomes than STR — correct.
- Craniospinal irradiation rationale (CSF seeding) and its retrospective PFS signal vs whole-brain/
  tumour-bed RT — grounded.
- Chemotherapy used for carcinoma (contrast with papilloma where it has no role); no single agreed
  regimen; classes cited (platinum, alkylators, etoposide, methotrexate, +/- anthracycline);
  pooled-analysis survival signal — grounded and appropriately caveated as small-series evidence.
- Age-based deferral of RT in infants using chemotherapy as a bridge — recognised strategy, correct.
- Germline TP53 / Li-Fraumeni association and clinical-genetics referral — well established, correct.
No fabricated or outdated regimen. No claim is mis-attributed to DeVita: where the source is silent
(extracranial TP53 surveillance protocol; preferred first-line regimen; RT dose/fractionation) the
draft explicitly says so ("What was deliberately left out"). Attribution discipline is good.

## 3. Dose-free
Confirmed. No mg, mg/m2, AUC, numbered schedule, or Gy value. "Higher fractionated doses have
correlated with better local control" refers to dose qualitatively with no numeric leak. PASS.

## 4. Scope
Appropriately scoped as decision-support, not a directive. Multidisciplinary referral, clinical-trial
enrollment, and genetics referral are surfaced. Explicitly defers regimen/dose selection to the
R1-gated structured protocol templates.

## 5. Adversarial flags
None to reconcile — no .verdict.md at the sidecar path.

## Blocking / Important / Advisory
- Critical: none.
- Important: none.
- Advisory: line 25 "possibly anthracycline-based therapy" is the weakest-evidence agent class;
  fine as written (already hedged "possibly"). Optional: label the CSI-vs-whole-brain and pooled-
  chemotherapy-survival claims as general-standard/retrospective-series evidence rather than implying
  a DeVita-specific endorsement — the draft already frames both as retrospective/pooled, so this is
  non-blocking.

APPROVE — clinically safe, grounded, no claim mis-attributed to DeVita, dose-free, appropriately scoped.
